A Phase 1 interventional study of [¹⁴C]-LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to eliminate it. This study will involve a single dose of ¹⁴C radiolabelled LY3502970. This means that a radioactive substance will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to 8 weeks (maximum).
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 3 milligrams (mg) of carbon-14-labeled \[¹⁴C\]-LY3502970, containing approximately 200 microcuries (µCi) of radioactivity on Day 1.
Drug: [¹⁴C]-LY3502970
Administered orally.
Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Feces excretion of LY3502970 radioactivity over time expressed as a percentage of the total radioactive dose administered. Feces samples collected from 0 hour (h), where 0h = time of dose administration, through 384h postdose were used to assess this outcome.
Time frame: 0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose
Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Urinary excretion of LY3502970 radioactivity over time expressed as a percentage of the total radioactive dose administered. Urine samples collected from 0 hour (h), where 0h = time of dose administration, through 384h postdose were used to assess this outcome.
Time frame: 0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration (AUC0- Tlast) of Plasma LY3502970
PK: AUC0-tlast of plasma LY3502970
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
PK: Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration ((AUC0- Tlast) of Total Radioactivity in Plasma and Whole Blood
PK: AUC0-tlast of total radioactivity in plasma and whole blood
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Plasma LY3502970
PK: AUC(0-∞) of plasma LY3502970
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Total Radioactivity in Plasma and Whole Blood
PK: AUC(0-∞) of total radioactivity in plasma and whole blood
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
PK: Maximum Concentration (Cmax) of Plasma LY3502970
PK: Cmax of plasma LY3502970
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood
PK: Cmax of total radioactivity in plasma and whole blood
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
Total Number of Metabolites of LY3502970 in Plasma, Urine and Feces
* Total number of metabolites of LY3502970 in plasma, urine and feces samples pooled across participants to assess the presence of metabolites. * Urine and feces samples collected as a 12-hour predose interval (-12 to 0 hour \[h\], where 0h = time of dose administration) and then continuously postdose in specified intervals through 384h were used to assess this outcome. * Feces Sample collection time frame : -12 to 0, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384h postdose
Time frame: Plasma: 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 h postdose; Urine: -12 to 0, 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384h postdose
| Milestone | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Started | 6 |
| Received at least one dose of study drug | 6 |
| Completed | 6 |
| Not completed | 0 |
Feces excretion of LY3502970 radioactivity over time expressed as a percentage of the total radioactive dose administered. Feces samples collected from 0 hour (h), where 0h = time of dose administration, through 384h postdose were used to assess this outcome.
| percentage of the total radioactive dose | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered | 86.75 ± 2.78 |
Urinary excretion of LY3502970 radioactivity over time expressed as a percentage of the total radioactive dose administered. Urine samples collected from 0 hour (h), where 0h = time of dose administration, through 384h postdose were used to assess this outcome.
| percentage of the total radioactive dose | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered | 0.24 ± 0.02 |
PK: AUC0-tlast of plasma LY3502970
| nanogram*hour per milliliter(ng*h/mL) | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration (AUC0- Tlast) of Plasma LY3502970 | 210 ± 14 |
PK: AUC0-tlast of total radioactivity in plasma and whole blood
| nanogram equivalents*hour per milliliter | 3mg [¹⁴C]-LY3502970 |
|---|---|
| AUC0-tlast of Plasma Total Radioactivity | 266 ± 21 |
| AUC0-tlast of Whole Blood Total Radioactivity | 103 ± 19 |
PK: AUC(0-∞) of plasma LY3502970
| nanogram*hour per milliliter(ng*h/mL) | 3mg [¹⁴C]-LY3502970 |
|---|---|
| PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Plasma LY3502970 | 223 ± 13 |
PK: AUC(0-∞) of total radioactivity in plasma and whole blood
| nanogram equivalents*hour per milliliter | 3mg [¹⁴C]-LY3502970 |
|---|---|
| AUC(0-∞) of Plasma Total Radioactivity | 292 ± 21 |
| AUC(0-∞) of Whole Blood Total Radioactivity | 135 ± 17 |
PK: Cmax of plasma LY3502970
| nanogram per milliliter(ng/mL) | 3mg [¹⁴C]-LY3502970 |
|---|---|
| PK: Maximum Concentration (Cmax) of Plasma LY3502970 | 10.4 ± 14 |
PK: Cmax of total radioactivity in plasma and whole blood
| nanogram equivalents per milliliter | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Cmax of Plasma Total Radioactivity | 10.7 ± 17 |
| Cmax of Whole Blood Total Radioactivity | 5.92 ± 16 |
* Total number of metabolites of LY3502970 in plasma, urine and feces samples pooled across participants to assess the presence of metabolites. * Urine and feces samples collected as a 12-hour predose interval (-12 to 0 hour \[h\], where 0h = time of dose administration) and then continuously postdose in specified intervals through 384h were used to assess this outcome. * Feces Sample collection time frame : -12 to 0, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384h postdose
| number of metabolites | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Plasma | 2 |
| Urine | NA |
| Feces | 12 |
Collected over Baseline up to Day 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3mg [¹⁴C]-LY3502970 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | 3mg [¹⁴C]-LY3502970 |
|---|---|
| NauseaGastrointestinal disorders | 5/6 |
| Abdominal distensionGastrointestinal disorders | 2/6 |
| DiarrhoeaGastrointestinal disorders | 2/6 |
| VomitingGastrointestinal disorders | 2/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/6 |
| Abdominal painGastrointestinal disorders | 1/6 |
| Vessel puncture site bruiseGeneral disorders | 1/6 |
| DizzinessNervous system disorders | 1/6 |
| Head discomfortNervous system disorders | 1/6 |
| HeadacheNervous system disorders | 1/6 |
All enrolled participants.
| Age, Continuous(years) | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Mean | 42.8 ± 8.0 |
| Sex: Female, Male(Participants) | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Female | 0 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | 3mg [¹⁴C]-LY3502970 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 6 |
| Race (NIH/OMB)(Participants) | 3mg [¹⁴C]-LY3502970 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | 3mg [¹⁴C]-LY3502970 |
|---|---|
| United Kingdom | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Jul 2021, 3 months.
Results were first posted in May 2026, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron